enGene Holdings Inc. announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company?s 2024 annual meeting of shareholders. enGene?s Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. Mr. Hastings has served as the President, Chief Executive Officer, and a member of the board of directors of Nkarta Inc. since February 2018.

Prior to that, he served as President, Chief Executive Officer, and Director of the OncoMed Pharmaceuticals Inc. from January 2006 until January 2018. In August 2013, he was elected Chairman of the board of directors of OncoMed and served in that role until January 2018. Prior to joining OncoMed, Mr. Hastings was President, Chief Executive Officer, and Director of QLT Inc., from February 2002 to September 2006.

From 2000 to 2002, Mr. Hastings served as President, Chief Executive Officer, and Director of Axys Pharmaceuticals Inc. Mr. Hastings was also previously the President of Chiron Biopharmaceuticals, a division of Chiron Corporation, President and Chief Executive Officer of LXR Biotechnology, and he held a variety of management positions of increasing responsibility at Genzyme Corporation, including President of Genzyme Therapeutics Europe and President of Worldwide Therapeutics. Mr. Hastings previously served on the board of directors of Relypsa, a publicly traded biotechnology company acquired by Galencia AG, as Chairman of the board of directors of Proteolix Inc., a privately held biopharmaceutical company acquired by Onyx Pharmaceuticals Inc., on the board of directors of ViaCell Inc. and as a director of ViaCyte Inc. Mr. Hastings currently serves as Chair of the board of Pacira Biosciences Inc. and the immediate past Chair and Board Executive Committee member of the Biotechnology Innovation Organization (BIO). Mr. Hastings received a B.S. in pharmacy from the University of Rhode Island.

Mr. Joustra is a General Partner at Forbion. At Forbion, he is responsible for deal origination, general portfolio management and divestment strategies, and focuses on Forbion?s Growth Opportunities Funds, which concentrates on investing in late-stage life sciences companies. Prior to joining Forbion in 2019, Mr. Joustra previously was a Senior Trader, as well as Executive Board member of the Life Sciences franchise at Kempen.

In this role he managed Kempen?s trading portfolio and was involved in deal structuring and equity capital markets transactions, as well as larger block trades. Mr. Joustra also served as a member of the board of directors of Gyroscope Therapeutics until the closing of its acquisition by Novartis in February 2022 for up to $1.5 billion, the board of directors of VectivBio from December 2022 until the closing of its $1.2 billion acquisition by Ironwood Pharmaceuticals in December 2023, the board of directors of Aiolos Bio until the closing of its acquisition by GSK plc in February 2024 for up to $1.4 billion and the board of Forbion European Acquisition Corporation, a special purpose acquisition company, until its completion of the business combination with enGene in October 2023. Currently Mr. Joustra serves on the board of directors of VectorY Therapeutics and holds a position as a board observer at NewAmsterdam Pharma N.V. He holds an M.Sc.

in Business Administration from the University of Groningen, and a B.Sc. in International Business and Management from this same university.